Evidence map›Paper›PMID 29578687›Full record

ArticleJournal of the American Chemical Society2018

Esterase-Catalyzed Siderophore Hydrolysis Activates an Enterobactin-Ciprofloxacin Conjugate and Confers Targeted Antibacterial Activity.

Wilma Neumann, Martina Sassone-Corsi, Manuela Raffatellu, Elizabeth M Nolan

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 140 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Re-evaluation of theBiochemistry · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wilma NeumannDepartment of Chemistry , Massachusetts Institute of Technology , Cambridge , Massachusetts 02139 , United States.ORCID 0000-0002-1728-5140
Martina Sassone-CorsiDepartment of Microbiology and Molecular Genetics , University of California , Irvine , California 92697 , United States.
Manuela RaffatelluDepartment of Microbiology and Molecular Genetics , University of California , Irvine , California 92697 , United States.
Elizabeth M NolanDepartment of Chemistry , Massachusetts Institute of Technology , Cambridge , Massachusetts 02139 , United States.ORCID 0000-0002-6153-8803
Massachusetts Institute of Technology · USUniversity of California, Irvine · US

Funding

Development of siderophore-based vaccines against non-typhoidal Salmonella infectionR01AI114625 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NOLAN, ELIZABETH M, RAFFATELLU, MANUELA · 2015 to 2019
$1.9M
Siderophore-based antibiotics: consequences for the microbiota and bacterial pathogensR21AI126465 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI NOLAN, ELIZABETH M, RAFFATELLU, MANUELA · 2016 to 2017
$404k
NIAID NIH HHS R01 AI114625NIAID NIH HHS R21 AI126465
6 · The paper itself

Abstract

Enteric Gram-negative bacteria, including Escherichia coli, biosynthesize and deploy the triscatecholate siderophore enterobactin (Ent) in the vertebrate host to acquire iron, an essential nutrient. We report that Ent-Cipro, a synthetic siderophore-antibiotic conjugate based on the native Ent platform that harbors an alkyl linker at one of the catechols with a ciprofloxacin cargo attached, affords targeted antibacterial activity against E. coli strains that express the pathogen-associated iroA gene cluster. Attachment of the siderophore to ciprofloxacin, a DNA gyrase inhibitor and broad-spectrum antibiotic that is used to treat infections caused by E. coli, generates an inactive prodrug and guides the antibiotic into the cytoplasm of bacteria that express the Ent uptake machinery (FepABCDG). Intracellular hydrolysis of the siderophore restores the activity of the antibiotic. Remarkably, Fes, the cytoplasmic Ent hydrolase expressed by all E. coli, does not contribute to Ent-Cipro activation. Instead, this processing step requires IroD, a cytoplasmic hydrolase that is expressed only by E. coli that harbor the iroA gene cluster and are predominantly pathogenic. In the uropathogenic E. coli UTI89 and CFT073, Ent-Cipro provides antibacterial activity comparable to unmodified ciprofloxacin. This work highlights the potential of leveraging and targeting pathogen-associated microbial enzymes in narrow-spectrum antibacterial approaches. Moreover, because E. coli include harmless gut commensals as well as resident microbes that can contribute to disease, Ent-Cipro may provide a valuable chemical tool for strain-selective modulation of the microbiota.

Indexed as

Anti-Bacterial AgentsBiocatalysisCiprofloxacinDose-Response Relationship, DrugEnterobactinEscherichia coliEsterasesHydrolysisMicrobial Sensitivity TestsMolecular ConformationStructure-Activity RelationshipAnti-Bacterial AgentsCiprofloxacinEnterobactinEsterases

Identifiers

PMID29578687
PMCPMC5921047
OpenAlexW2790632147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.